Form 8-K - Current report:
SEC Accession No. 0001193125-24-130779
Filing Date
2024-05-03
Accepted
2024-05-03 16:24:58
Documents
15
Period of Report
2024-05-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d835891d8k.htm   iXBRL 8-K 58468
2 EX-99.1 d835891dex991.htm EX-99.1 7986
6 GRAPHIC g835891image001.jpg GRAPHIC 1906
  Complete submission text file 0001193125-24-130779.txt   205581

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA grtx-20240502.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE grtx-20240502_lab.xml EX-101.LAB 18723
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grtx-20240502_pre.xml EX-101.PRE 11706
18 EXTRACTED XBRL INSTANCE DOCUMENT d835891d8k_htm.xml XML 3841
Mailing Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355
Business Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

EIN.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39114 | Film No.: 24913548
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)